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Abstract
Background: Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with chronic
kidney disease (CKD). Cardiovascular risk assessment in this population is hampered by the failure of traditional risk
factors to fully account for the elevated CVD risk (reverse epidemiology effect) and the presence of emerging risk
factors specifically related to kidney failure. Therefore, diagnostic tools capable of improving cardiovascular risk
assessment beyond traditional risk factors are currently warranted. We present the protocol of a 4-year prospective
study aimed to assess the predictive value of non-invasive imaging techniques and biomarkers for CVD events and
mortality in patients with CKD.
Methods: From November 2009 to October 2010, 4137 asymptomatic adult patients with stages 2 to 5 CKD will
be recruited from nephrology services and dialysis units throughout Spain. During the same period, 843
participants without CKD (control group) will be recruited from lists of primary care physicians, only at baseline.
During the follow-up, CVD events and mortality will be recorded from all CKD patients. Clinical and laboratory
characteristics will be collected in a medical documentation sheet. Three trained itinerant teams will carry out a
carotid ultrasound to assess intima-media thickness and presence of plaques. A composite atherosclerosis score will
be constructed based on carotid ultrasound data and measurement of ankle-brachial index. In CKD patients,
presence and type of calcifications will be assessed in the wall of carotid, femoral and brachial arteries, and in
cardiac valves, by ultrasound. From all participants, blood samples will be collected and stored in a biobank to
study novel biomarkers.
Conclusions: The NEFRONA study is the first large, prospective study to examine the predictive value of several
non-invasive imaging techniques and novel biomarkers in CKD patients throughout Spain. Hereby, we present the
protocol of this study aimed to explore the most effective way in which these tests can be integrated with
traditional risk factors to maximize CVD detection in this population.
Background
Cardiovascular disease (CVD) is the leading cause of
cardiovascular morbidity and mortality in patients with
chronic kidney disease (CKD) [1,2]. This association is
even more evident in dialysis patients, where CV mor-
tality accounts for 45% of all-cause mortality [3].
Therefore, as stated by the American Heart Association
(AHA), CKD patients should be considered as CHD risk
equivalent for risk factor management [4].
Multivariable mathematical functions based on tradi-
tional cardiovascular risk factors, such as the Framing-
ham Risk Score charts [5], have been developed for
predicting CVD risk in individual patients. However,
these risk equations provide an inadequate warning to
asymptomatic patients with CKD due to the reverse epi-
demiology effect [6], by which traditional risk factors fail
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lation, and the presence of non-traditional biomarkers
specifically related to kidney failure per se [7]. Moreover,
recent studies suggest only limited utility of either single
or multiple biomarkers of inflammation, oxidative stress,
anemia, endothelial dysfunction, vascular calcification
and electrolyte imbalance, as prognostic tools of patients
with CKD [8]. Therefore, as discussed by the Screening
for Heart Attack Prevention and Education (SHAPE)
Task Force [9], additional tools capable of improving
cardiovascular risk assessment beyond traditional risk
factors are clearly warranted in this population.
Among these techniques, carotid ultrasound and
ankle-brachial index (ABI) are non-invasive, simple,
widely available, relatively inexpensive, and generally
reproducible methods to assess carotid atherosclerosis
and peripheral arterial disease (PAD), respectively
[10,11]. Several prospective studies [12,13] in the general
population have shown that an increased carotid intima-
media thickness (CIMT) and/or abnormal ABI are asso-
ciated with a higher CVD risk, independently of tradi-
tional risk factors. Prior studies have also examined the
prognostic value of CIMT [14-18] or ABI [19,20] in
CKD patients. However, most of them were conducted
in patients on dialysis therapy, except by Szeto et al [18]
who analyzed the predictive role of CIMT in a small
sample of patients in predialysis. This group of investi-
gators [18] also found that CIMT was a valuable tool
for CVD risk stratification. Therefore, further studies are
needed to ascertain the predictive role of these tests,
particularly in early stages of CKD.
On the other hand, CKD patients have a higher preva-
lence of alterations in their calcium and phosphorus
homeostasis that ultimately result in vascular calcifica-
tions. Presence of vascular calcifications in the arterial
walls and cardiac valves has been associated with an
increased risk for CV events and mortality [21,22]. How-
ever, the impact on prognosis according to the extent
and type of calcification (intimal vs. medial) remains still
unclear [23,24].
Therefore, the NEFRONA study is aimed to assess
atherosclerosis burden and vascular calcifications in a
large cohort of Spanish patients with CKD. This study
will also examine the predictive value of non-invasive
imaging techniques and novel biomarkers influencing
cardiovascular events and mortality in all forms of CKD.
Finally, the present study will allow us to assess whether
these tests can be integrated with traditional risk factors
to maximize early-detection of CVD in this population.
Methods
Study Design
In a multicenter, prospective (four years of follow-up)
study, 4137 patients with CKD will be enrolled from
November 2009 to October 2010. CKD patients will be
r e c r u i t e df r o md i f f e r e n th o spitals throughout Spain
referred by their nephrologists. All patients will undergo:
1. ultrasound assessment of carotid, femoral and bra-
chial arteries, 2. ABI, and 3. echocardiography. These
tests will be carried out according to a common proto-
col by three trained itinerant teams composed each one
of a technician and a nurse. During the same period,
843 patients without CKD (control group) will be
recruited from lists of primary health physicians. The
local Ethics Committee of the Hospital Arnau de Vila-
nova approved the protocol. All subjects will provide
informed consent to participate in the study.
Study participants
Participants will be eligible for inclusion if they (1) have
CKD (glomerular filtration rate (GFR) < 60 ml/min per
1.73 m
2) stages 2 to 5, and (2) ages of 18 to 74 years.
Patients undergoing hemodialysis (HD) or peritoneal
dialysis (PD) will be also invited to participate. The
study is designed to use a population control as refer-
ence group. Eligible controls will be asymptomatic sub-
jects without CKD. Participants will be excluded for any
of the following reasons: (1) had prior CVD, (2) received
a kidney transplant, (3) had a life-threatening disease,
such as cancer, (4) underwent previous carotid artery
surgery, or (5) have an ABI < 0.7 and/or a carotid artery
stenosis greater than 75% at baseline.
We will use the Modification of Diet in Renal Disease
S t u d y( M D R D )a n dt h eC h r o n i cK i d n e yd i s e a s eE p i d e -
miology Collaboration (CKD-EPI) equations to estimate
the GFR to classify patients into the different stages of
CKD [25,26]. Patients switching stage or dialytic modal-
ity in the follow-up of this study will be considered and
these data will be registered at each visit. Only patients
who switch to kidney transplant will be excluded from
the follow-up. Enrollment will be stratified by hospital
according to the prevalence of CKD patients in each
stage, in order to obtain a sample in which all Spanish
regions would be represented. Details about centers and
geographical distribution can be seen at the website of
the NEFRONA study http://www.nefrona.es.
Clinical and laboratory characteristics
At each study visit, physicians responsible for the
recruitment of participants will be asked to complete a
medical questionnaire in patients with (Table 1) and
without (Table 2) CKD. Briefly, these questionnaires will
include data regarding family history of early-onset
CVD, clinical history, cardiovascular risk factors, analytic
values, and medication use. Information on smoking
habit and alcohol intake (grams of alcohol) will be
obtained by direct questioning. Anthropometrical data
will be obtained by standard methods. Weight will be
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Page 2 of 8Table 1 Questionnaire in patients with chronic kidney disease (CKD)
INDIVIDUAL PATIENT DATA Date ____/____/________
Centre: Identification number:
Sex: men □ women □ Age:
Visit: V OV 1V 2V 3V 4 CKD stage: 2345
Glomerular Filtration Rate (CKD-EPI): CKD etiology:
DIALYSIS: Yes □ No □ Modality: HD □ PD □ Time on dialysis (months):
HEMODIALYSIS (HD): membrane type: low flux □ high flux □
Frequency HD: 3 d/week □ /48 h □ /24 h □ Duration HD (hours):
KtV (last measured value):
Type of HD access: arteriovenous shunt □ graft □ catheter □
PERITONEAL DIALYSIS (PD): Type: Automatic □ Manual □
Transport type: low □ high □ Icodextrin administration: Yes □ No □
Total infused volume (ml): Total eliminated volume (ml):
diuresis volume (ml): residual renal function (ml/min):
Total KtV (last measured value): peritoneal ktV (last measured value):
Peritonitis (last year): Yes □ No □ number of peritonitis:
COMORBIDITIES
Diabetes: Yes □ No □
Hypertension: Yes □ No □
Heart failure: Yes □ No □
Atrial fibrillation: Yes □ No □
Dyslipidemia: Yes □ No □
Family history of early cardiovascular disease: Yes □ No □
Parathyroidectomy: Yes □ No □
LABORATORY DATA Date ____/____/________
Hemoglobin (g/dl): Urea (mg/dl):
Hematocrit (%): Uric acid (mg/dl):
Iron (mg/dl): Glucose (mg/dl):
Transferrin (mg/dl): HbA1c (%):
Ferritin (ng/ml): Insulin (U/l):
Total calcium (mg/dl): Cystatin C (mg/l):
Phosphorus (mg/dl): Total cholesterol (mg/dl):
Intact parathormone level (pg/mL): Triglycerides (mg/dl):
Sodium (mEq/L): HDL cholesterol (mg/dl):
Potassium (mEq/L): LDL cholesterol (mg/dl):
Albumin (g/dl): Hepatitis C virus positive: Yes □ No □
Creatinin (mg/dl): Microalbuminuria (mg/l) (urine):
AST/ALT (U/L): Albumin/creatinin (mg/g) (urine):
MEDICAL TREATMENT Platelet inhibitors: Yes □ No □
Antihypertensives: Yes □ No □ Oral anticoagulants: Yes □ No □
Length of treatment (months): Phosphate binders: CO3Ca □ sevelamer □
Angiotensio-converting enzyme (ACE) calcium acetate □ Al(OH)3 □ lanthane □
inhibitors: Yes □ No □ Total dose (g/day):
Angiotensin II receptor blockers Lenght of treatment (months):
(ARB): Yes □ No □ Vitamin D analogues/metabolites: Yes □ No □
Hypolipidemics: statins □ fibrates □ Type:
Length of treatment (months): Total dose (mcg/week):
Insulin: Yes □ No □ Length of treatment (months):
Oral antidiabetics: Yes □ No □ Erythropoiesis-stimulating agents: Yes □ No □
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Page 3 of 8measured with a beam balance and height with fixed
stadiometer. BMI will be calculated as weight, in kilo-
grams, divided by the square of height, in meters. Waist
circumference will be measured at the umbilicus, mea-
sured in meters. Blood pressure will be measured in
duplicate with a validated semi-automatic oscillometer
(Omron HEM-705CP) while patients are seated and had
rested for five min. Hypertension will be defined as sys-
tolic blood pressure (BP) ≥140 mmHg, diastolic BP ≥90
mmHg, or current use of antihypertensive medication.
Diabetes mellitus will be defined as a fasting glucose
level ≥126 mg/dL (6.93 mmol/L) or treatment with anti-
diabetic agents. Analytic values will be obtained in fast-
ing from recent clinical records.
Clinical follow-up and end-points
All CKD patients will be monitored each year for
4 years or until death, disenrollment from the hospital,
or kidney transplantation. The clinical management will
be decided by individual physician without being
affected by the study. Primary end-points will be CVD
events according to the International Classification of
Diseases, Ninth Revision, Clinical Modification (ICD9-
CM) which includes unstable angina, myocardial infarc-
tion, transient ischemic attack, cerebrovascular accident,
congestive heart failure, arrhythmia, PAD or amputation
for vascular disease and aorta aneurism. At each visit,
all-cause and cardiovascular mortality will be also regis-
tered. All-cause mortality will comprise infections,
tumors, accidents, and uremia. Cardiovascular mortality
causes will include myocardial infarction, arrhythmia,
congestive heart failure, stroke, aneurism, mesenteric
infarction, and sudden death. Importantly, CVD events
and deaths will be accurately recorded by each physician
responsible of the recruitment of CKD patients. In the
case of an out-of-hospital death, family members will be
Table 2 Questionnaire in subjects with normal renal function (control group)
INDIVIDUAL PATIENT DATA
Centre: Identification number:
Sex: men □ women □ Age:
COMORBIDITIES
Diabetes: Yes □ No □
Hypertension: Yes □ No □
Heart failure: Yes □ No □
Atrial fibrillation: Yes □ No □
Dyslipidemia: Yes □ No □
Family history of early cardiovascular disease: Yes □ No □
Parathyroidectomy Yes □ No □
LABORATORY DATA Date ____/____/________
Hemoglobin (g/dl): Urea (mg/dl):
Hematocrit (%): Uric acid (mg/dl):
Iron (mg/dl): Glucose (mg/dl):
Transferrin (mg/dl): HbA1c (%):
Ferritin (ng/ml): Insulin (U/l):
Total calcium (mg/dl): Cystatin C (mg/l):
Phosphorus (mg/dl): Total cholesterol (mg/dl):
Intact parathormone level (pg/mL): Triglycerides (mg/dl):
Sodium (mEq/L): HDL cholesterol (mg/dl):
Potassium (mEq/L): LDL cholesterol (mg/dl):
Albumin (g/dl): Hepatitis C virus positive: Yes □ No □
Creatinin (mg/dl): Microalbuminuria (mg/l) (urine):
AST/ALT (U/L): Albumin/creatinin (mg/g) (urine):
MEDICAL TREATMENT
Antihypertensives: Yes □ No □
Length of treatment (months):
Angiotensio-converting enzyme (ACE) inhibitors: Yes □ No □
Angiotensin II Receptor Blockers (ARB): Yes □ No □
Hypolipidemics: statins □ fibrates □ Length of treatment (months):
Insulin: Yes □ No □ Oral antidiabetics: Yes □ No □
Platelet inhibitors: Yes □ No □ Oral anticoagulants: Yes □ No □
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Page 4 of 8interview by telephone to better ascertain the circum-
stances surrounding death.
Secondary end-points will be CIMT and plaque pre-
sence, by ultrasound; ABI measurement; presence of cal-
cifications in carotid, femoral, and brachial arteries and
in cardiac valves, by ultrasound; left ventricular (LV)
hypertrophy, LV ejection fraction, left atrial size, and LV
diastolic filling, by echocardiography; and biomarkers.
These tests will be performed during a midweek dialysis
day in HD patients and on a full abdomen in PD
patients.
Carotid ultrasound
B-mode ultrasound imaging of the right and left caro-
tid arteries will be performed using a General Electric
instrument (Vivid i BT09 model) equipped with 6-13
MHz broadband linear array transducers. Participants
will be examined in the supine position with the head
turned 45°contralateral to the side of scanning. Prior
to obtaining images for CIMT measurements, B-mode
and color Doppler sonographic examinations will be
done in longitudinal and transverse planes to identify
vascular stenosis. A standardized imaging protocol will
be use for CIMT measurements. With the carotid dila-
tation and flow dividers as anatomic landmarks, the
sonographer will obtain high-resolution images of the
common carotid (1 cm proximal to the bifurcation),
the bifurcation (between dilatation and flow divider)
and the internal carotid (1 cm distal to the flow divi-
der). A single lateral angle of insonation, optimizing
the image for the arterial far wall, will be use. Plaques
will be sought by using B-mode and color Doppler
examinations in both longitudinal and transverse
planes to take into consideration circumferential asym-
metry and will be defined as focal intrusions into the
lumen ≥1.2 mm thick. We will consider severe stenosis
if systolic velocity peak is higher or equal than
125 cm/s. We will define the following variables:
1. mean CIMT, defined as the average of 4 to 8 dis-
tances between the far wall lumen-intima and media-
adventicia ultrasound interfaces taken bilaterally in
each of the specified segments mentioned above, and
2. maximum CIMT, defined as the maximum distance
in each segment. CIMT measurements will be made in
plaque-free arterial segments. Digital images from dia-
stolic frame recordings will be electronically trans-
ferred to an offline workstation (Hospital Arnau de
Vilanova, Lleida, Spain) for quantification of CIMT
measurements. Three certified ultrasound readers, una-
ware of patient clinical information, will review the
scans and will made CIMT quantitative measurements,
using a semi-automated edge-tracking software (Sono-
Calc IMT®) based on detection of the echo structures,
with the option of making manual corrections.
Ankle-brachial index (ABI)
From all participants, ABI will be obtained using a vas-
cular Doppler MD2 Hungleight with an 8 MHz transdu-
cer. ABI is defined as the ratio of the systolic BP at the
ankle to the systolic BP in the arm. A hand-held Dop-
pler will be used to assess bilateral brachial, tibial and
dorsalis pedis arteries. At each ankle (right and left), the
higher of the two pressures measured in each leg will be
used as the numerator for same-side ABI calculation.
We will record ABI as the lowest value obtained at each
territory.
Atherosclerosis score
Based on carotid ultrasound data and ABI measurement,
we will set up an atherosclerosis score (AS) defined as
follows (Figure 1):
1. No atherosclerosis (AS 0): ABI >0.9 and CIMT
values <90th percentile of reference values [26].
2. Mild atherosclerosis (A S1 ) :a nA B Ib e t w e e n0 . 7 -
0.9 or CIMT values ≥90th percentile of reference
values.
3. Moderate atherosclerosis (AS 2): carotid plaque
with stenosis <75%.
4. Severe atherosclerosis (AS 3): an ABI <0.7 or car-
otid plaque with stenosis ≥75%.
Vascular calcifications
In CKD patients, vascular calcifications will be assessed
by B-mode ultrasound in both sides of carotid, femoral,
and brachial arteries. Carotid calcifications will be
assessed in each of the specified carotid segments men-
tioned above, whereas femoral calcifications will be
examined in common and superficial femoral arteries.
Highly echogenic plaques producing bright white echoes
with shadowing will be considered to be calcifications.
Arterial calcifications at each arterial site will be quanti-
fied qualitatively as absent (0) or present (1). The final
Figure 1 Atherosclerosis score (AS) distribution depending on
carotid ultrasound data and ankle-brachial index (ABI).
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Page 5 of 8score will be obtained by the addition of calcifications
from all studied territories, ranging from 0 (absence of
calcium deposit) to 12 (calcifications present in all terri-
tories examined). Type of calcifications will be also
registered according to their location in the arterial wall,
as follows: intimal, medial or both (plaque presence).
Three certified ultrasound readers, unaware of patient
clinical information, will review the scans and will deter-
mine the calcification score.
Echocardiography
A standard two-dimensional M-mode color Doppler
echocardiography will be performed on CKD patients
using a 3 MHz transducer (General Electric Vivid i
BT09). LV mass will be calculated as follows: 0.8 × [1.04
×( P W T+I V S T+L V E D D )
3 -L V E D D
3]-1 3 . 6 ,w h e r e
PWT is the posterior wall thickness, IVST is the inter-
ventricular septal thickness and LVEDD is the LV end-
diastolic diameter. LV mass will be normalized to body
height as an index in g/m
2. LV hypertrophy will be
defined according to Framingham’s criteria (LV mass/
body surface area [BSA] >110 g/m
2 in females and LV
mass/BSA >134 g/m
2 in males) [28]. LV ejection frac-
tion and left atrial size will be also measured. LV diasto-
lic filling will be evaluated from pulsed Doppler studies
obtained from the apical four-chamber view of the
heart. Maximal early diastolic flow velocity (E) and max-
imal late atrium flow velocity (A) will be measured and
their ratio (E/A) calculated. Presence of calcifications in
mitral and aortic valves (yes/no) will be also evaluated.
All images will be sent to one study site (Hospital Clín-
ico San Carlos, Madrid, Spain) for analysis by two certi-
fied readers blinded to clinical data.
Biomarkers
Samples will be collected of whole blood into 10 ml
EDTA vacutainers, maintained at ambient temperature
and transported overnight to a centralized biobank
named REDinREN (Spanish Renal Research Network).
These samples will be processed immediately after their
reception by a laboratory technique according to the
biobank protocol [29]. Plasma, serum, DNA and RNA
will be collected from all participants. These samples
will be frozen and stored in the biobank until their use.
Sample size calculation
The sample size needed to address the objectives of this
study has been estimated with the following assumptions:
alpha 5%, beta 10% (power 90%), loss to follow-up 25%,
and revised incidence of CV outcomes at each CKD stage
[2]. Based on these data, the target number for inclusion
of patients with CKD will be 4137, distributed for each
stage as follows: 1476 (stage 2), 1325 (stage 3), 713
(stages 4 and 5), and 623 (patients in dialysis treatment,
either HD or PD). The sample size of the control group
will be 843 based on minimal detectable differences in
plaque presence between patients with and without CKD
(personal data from Hospital Arnau de Vilanova).
Statistical Analyses
SPSS software (version 17.0) will be used for statistical
analyses. Data will be presented as means ± SE for contin-
uous variables and as frequencies or percentages for cate-
gorical variables. Differences in mean values will be
assessed by analysis of variance and unpaired t-tests, or
the Mann Whitney U-test when the variables have a
skewed distribution. Categorical variables will be com-
pared by using the Pearson chi-square or the Fisher’s
exact tests. The relationship between measured primary
and secondary end-points will be analyzed by multivariate
Cox regression. Survival curves will be constructed using
the Kaplan-Meier method, and long-rank test will be used
for exploratory univariate analysis of survival differences
between groups. We will use ROC curves analysis to cal-
culate the additional predictive value for CV outcomes of
imaging parameters and biomarkers beyond and above
that provided by traditional risk factors. Two-sided P
values <0.05 will be considered statistically significant.
Discussion
The present study is the first large, prospective, observa-
tional study to examine the usefulness of different non-
invasive imaging techniques and biomarkers to predict
CVD events and mortality in CKD patients throughout
Spain. Given the paradoxical associations between tradi-
tional risk factors and CVD risk in patients with CKD,
additional diagnostic tools are currently warranted to
identify the real cardiovascular culprits. Hereby, we pre-
sent the protocol of the NEFRONA study aimed to
explore the most effective way in which these tests can
be integrated with current clinical laboratory markers to
maximize their synergism for CVD detection.
CIMT is a well-documented surrogate marker of pre-
clinical atherosclerosis, by which higher CIMT measure-
ments have been associated with an increased risk of
CVD [11]. Several prior studies have assessed its predic-
tive role in healthy subjects [12] and CKD patients
[14-18]. However, most studies in CKD patients have
been performed in small samples of patients undergoing
dialysis therapy. Only Szeto et al [18] assessed CIMT in
a sample of 203 Chinese patients on predialysis. The
authors concluded that CIMT was a strong predictor of
CVD and might be usefully applied for risk stratification
in this group of patients. ABI as a surrogate marker to
predict PAD, has also been assessed as a predictor of
CVD mortality only in dialysis patients [19,20]. There-
fore, the predictive value of either CIMT or ABI in early
stages of CKD remains still unknown.
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CKD, and several investigators have demonstrated that
presence and extent of vascular calcifications is an inde-
pendent predictor of CV mortality [21-23]. Interestingly,
Blacher et al [23] studied the prognostic value of calcifi-
cations in carotid artery, abdominal aorta, iliofemoral
axis, and legs in 110 patients on HD therapy, reporting
an increased risk of death in those patients with a
higher number of calcified vascular sites. However, only
one study [24] has examined the predictive value of type
of arterial calcifications (intimal vs. medial) in 202 HD
patients using radiographs of the pelvis and the thigh.
London et al [24] found that intimal calcification was
associated with atherosclerotic complications whereas
medial calcification, with CKD specific risk factors.
Moreover, the authors reported higher rates of CVD
mortality in patients with intimal calcification. Further
studies are currently warranted in order to clarify the
importance of extent and type of vascular calcifications
in different arterial territories and in large samples of
patients with all sorts of CKD.
Calcifications of cardiac valves have also been asso-
ciated with an increased risk for mortality and CVD
events in healthy populations [21]. In CKD patients, only
two prior small studies have examined the predictive role
of cardiac valve calcifications with controversial results
[30,31]. In this regard, Wang et al [30] reported that pre-
sence of calcified cardiac valves was predictive of all-
cause mortality and cardiovascular death in 192 patients
on dialysis. By contrast, Panuccio et al [31] did not find
an association between cardiac valve calcifications and
cardiovascular mortality in 202 HD patients. In addition,
prior small studies have identified a number of echocar-
diographic variables, including left atrial size, LV hyper-
trophy, and LV filling pressure, that predict CVD events
and mortality in dialysis patients [32,33]. However, no
prospective studies have assessed their predictive value in
predialysis patients. Thus, the NEFRONA study will pro-
vide us compelling evidence regarding the prognostic
role of cardiac valve calcifications and several ecocardio-
graphic variables in CKD patients. Moreover, this study
may help us to understand the link between calcifications
in the arterial walls or cardiac valves and atherosclerosis,
a question that to date remains undetermined.
On the other hand, the collection of plasma, DNA and
RNA samples in this study will contribute to a better
assessment of CVD in renal patients. Although recent
studies [8] suggest only limited utility of either single or
multiple biomarkers of CVD risk as prognostic tools in
CKD patients, their integration with traditional markers
to maximize CVD detection in this population remains
to be established. Of note, identification of specific
genetic variants acting in the arterial walls will allow us
to develop genetic screening tools for diagnosis and
therapeutic interventions. Likewise, RNA samples will
enable us to understand the molecular mechanisms lead-
ing to atherosclerosis in these patients, contributing to
the reduction of their morbimortality risk due to CVD.
O v e r a l l ,t h eN E F R O N As t u d ym a yp r o v i d en e w
insights into the natural course, genotype-phenotype
interactions and pathophysiology of CKD, providing
new targets for early diagnosis and therapy for CVD in
these patients. The present study has several strengths,
i n c l u d i n gt h el a r g es a m p l es i z en a t i o n a l l yr e p r e s e n t a -
tive, the complete nature of the dataset, the existence
of a central biobank, the use of clinically important
primary end-points (CV morbidity and all-cause and
CV mortality), the performance of all imaging techni-
ques by three trained itinerant teams using a common
protocol, and the large follow-up period of this study
(4 years). Importantly, the longitudinal nature of the
present study will allow us to determine the temporal
and causal relationships among CVD risk factors,
CKD, imaging parameters, and biomarkers. However,
there are some limitations to our study. First, estima-
tion of kidney function by determination of serum
creatinine may be responsible for misclassification of
some participants in the analyses by stage of kidney
function; however, its determination will be made
using the Jaffe kinetic method by all participating cen-
ters. Second, we will use estimated GFR rather than
more precise measures of kidney function, like iothala-
mate clearance. Finally, prevalent dialysis patients will
be included, which may introduce survival bias because
of early mortality.
Conclusions
In conclusion, the NEFRONA study will examine
whether non-invasive imaging techniques and biomar-
kers may increase the predictive power to detect CV
morbidity and mortality in asymptomatic CKD patients,
beyond traditional risk factors. Moreover, the present
study may enable us to understand the molecular
mechanisms leading to atherosclerosis in these patients,
contributing to the reduction of their morbimortality
risk due to CVD.
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